Mean Percent Changes in AGT Over Time in IONIS-AGT-LRx Versus Placebo in the Monotherapy Study
The shaded area represents the dosing window, the arrowheads show the timepoint when the dose was given, and the unshaded area shows the follow-up period. The primary endpoint was at day 43. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 IONIS-AGT-LRx versus placebo at the specified timepoint. AGT = angiotensinogen.